Eye-Strengthening light therapy tested to halt blinding cornea disease
NCT ID NCT01604135
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a procedure called corneal collagen crosslinking for people with progressive keratoconus, a condition where the cornea thins and bulges, blurring vision. The treatment uses riboflavin (vitamin B2) drops and UV light to stiffen the cornea. The study aims to see if it can stop the cornea from getting steeper over 12 months, potentially preventing the need for a cornea transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
corneal collagen crosslinking (a procedure using riboflavin drops and UV light to strengthen the cornea)
What this could lead to
If it works, this could offer a way to halt keratoconus progression and avoid the need for a cornea transplant.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. The procedure may not stop progression in all cases, and there are risks like infection or corneal haze.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KERATOCONUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Ophthalmology, Sahlgrenska University Hospital
Mölndal, Västra Götalandsregionen, 43180, Sweden